Home › Companies › TRAVERE THERAPEUTICS INC. › 2024-2025
Compiled from SEC Form N-PX filings and TRAVERE THERAPEUTICS INC.’s Form 8-K (Item 5.07 on EDGAR). Page generated 04 October 2026.
Explore TRAVERE THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are TRAVERE THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Roy D. Baynes, M.D., Ph.D. | 73,899,556 | -- | -- | 755,457 | 4,400,125 | Majority: yes |
| Elect Director: Suzanne Bruhn, Ph.D. | 73,883,211 | -- | -- | 771,802 | 4,400,125 | Majority: yes |
| Elect Director: Timothy Coughlin | 73,659,261 | -- | -- | 995,752 | 4,400,125 | Majority: yes |
| Elect Director: Eric Dube, Ph.D. | 74,221,146 | -- | -- | 433,867 | 4,400,125 | Majority: yes |
| Elect Director: Gary Lyons | 73,773,536 | -- | -- | 881,477 | 4,400,125 | Majority: yes |
| Elect Director: Jeffrey Meckler | 71,792,648 | -- | -- | 2,862,365 | 4,400,125 | Majority: yes |
| Elect Director: John A. Orwin | 73,064,344 | -- | -- | 1,590,669 | 4,400,125 | Majority: yes |
| Elect Director: Sandra Poole | 73,951,215 | -- | -- | 703,798 | 4,400,125 | Majority: yes |
| Elect Director: Ron Squarer | 74,003,330 | -- | -- | 651,683 | 4,400,125 | Majority: yes |
| Elect Director: Ruth Williams-Brinkley | 74,000,702 | -- | -- | 654,311 | 4,400,125 | Majority: yes |
| Proposal 2: Approval of the Company's 2018 Equity Incentive Plan, as amended The Company's stockholders approved the 2018 Plan, as amended, to increase the number of shares of common stock authorized for issuance thereunder by 4,000,000 | 71,802,001 | 2,812,989 | 40,020 | -- | 4,400,125 | Majority: yes |
| Proposal 3: Approval, on an advisory basis, of the compensation of the Company's named executive officers The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers | 71,929,269 | 2,677,694 | 48,048 | -- | 4,400,125 | Majority: yes |
| Proposal 4: Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection by the Audit Committee of Ernst & Young LLP as the Company's independent registered public accounting firm for the fisc | 79,001,421 | 46,742 | 6,972 | -- | -- | Majority: yes |
Source: TRAVERE THERAPEUTICS INC., Form 8-K — read the filing on EDGAR.
Each item below shows how the 233 asset managers that disclosed a TRAVERE THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of TRAVERE THERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Meeting held 2025-05-15.
Combines 8 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
TRAVERE THERAPEUTICS INC.’s own tally for this item (“Proposal 3: Approval, on an advisory basis, of the compensation of the Company's named executive officers The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive offic”): 71,929,269 for, 2,677,694 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 88,787,429 outstanding shares: 81% for, 3% against (84% of the company cast a for/against vote).
The 228 asset managers below cast 98% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Janus Henderson | 7,189,106 | 0 | 0 | 0 | For |
| ARMISTICE CAPITAL, LLC | 7,122,955 | 0 | 0 | 0 | For |
| BlackRock | 6,309,150 | 0 | 0 | 0 | For |
| Vanguard | 5,067,400 | 0 | 0 | 0 | For |
| State Street | 5,065,539 | 0 | 0 | 0 | For |
| MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST | 4,341,874 | 0 | 0 | 0 | For |
| Fidelity | 3,851,439 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 3,563,534 | 0 | 0 | 0 | For |
| Rock Springs Capital Management LP | 3,047,937 | 0 | 0 | 0 | For |
| VIKING GLOBAL INVESTORS LP | 2,714,939 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2,084,898 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,972,840 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,967,134 | 0 | 0 | 0 | For |
| Two Sigma | 1,550,516 | 0 | 0 | 0 | For |
| Renaissance | 1,529,368 | 0 | 0 | 0 | For |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 1,481,845 | 0 | 0 | 0 | For |
| Charles Schwab | 1,355,001 | 0 | 0 | 0 | For |
| Federated Hermes | 1,221,691 | 0 | 0 | 0 | For |
| Nuveen | 1,203,720 | 0 | 0 | 0 | For |
| TIAA | 1,195,261 | 0 | 0 | 0 | For |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,120,550 | 0 | 0 | 0 | For |
| EMERALD ADVISERS, LLC | 1,059,727 | 0 | 0 | 0 | For |
| DE Shaw | 1,004,382 | 0 | 0 | 0 | For |
| Prudential/PGIM | 915,400 | 0 | 0 | 0 | For |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 911,054 | 0 | 0 | 0 | For |
Showing the 25 largest of 228 asset managers. See all 228 in the interactive database.
Meeting held 2025-05-15.
Combines 5 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
TRAVERE THERAPEUTICS INC.’s own tally for this item (“Proposal 2: Approval of the Company's 2018 Equity Incentive Plan, as amended The Company's stockholders approved the 2018 Plan, as amended, to increase the number of shares of common stock authorized for issuance thereun”): 71,802,001 for, 2,812,989 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 88,787,429 outstanding shares: 81% for, 3% against (84% of the company cast a for/against vote).
The 76 asset managers below cast 98% of the shares they voted on this item FOR (27,561,485 for, 619,733 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,872,941 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 3,563,534 | 0 | 0 | 0 | For |
| BlackRock | 3,221,313 | 0 | 0 | 0 | For |
| Fidelity | 2,810,998 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,972,840 | 0 | 0 | 0 | For |
| State Street | 1,756,896 | 122 | 0 | 0 | For |
| TIAA | 1,195,261 | 0 | 0 | 0 | For |
| Eversept Partners, LP | 867,554 | 0 | 0 | 0 | For |
| Charles Schwab | 677,479 | 0 | 0 | 0 | For |
| Prudential/PGIM | 216,661 | 393,263 | 0 | 0 | Against |
| Federated Hermes | 578,163 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 534,643 | 0 | 0 | 0 | For |
| FINANCIAL INVESTORS TRUST | 494,279 | 0 | 0 | 0 | For |
| Principal | 480,290 | 0 | 0 | 0 | For |
| Aberdeen | 403,891 | 0 | 0 | 0 | For |
| IMPAX FUNDS SERIES TRUST I | 300,000 | 0 | 0 | 0 | For |
| Waddell & Reed | 271,855 | 0 | 0 | 0 | For |
| Equitable | 250,620 | 0 | 0 | 0 | For |
| John Hancock | 26,913 | 193,041 | 0 | 0 | Against |
| SUPERSTRING CAPITAL MANAGEMENT LP | 219,539 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 209,000 | 0 | 0 | 0 | For |
| JPMorgan | 190,779 | 0 | 0 | 0 | For |
| GuideStone | 161,040 | 0 | 0 | 0 | For |
| Lincoln Financial | 124,966 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 124,943 | 0 | 0 | 0 | For |
Showing the 25 largest of 76 asset managers. See all 76 in the interactive database.
Meeting held 2025-05-15.
Combines 3 wordings of this item as funds reported it.
99.9% Majority: yes · of votes cast
TRAVERE THERAPEUTICS INC.’s own tally for this item (“Proposal 4: Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection by the Audit Committee of Ernst & Young LLP as the Company's independent regist”): 79,001,421 for, 46,742 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 88,787,429 outstanding shares: 89% for, 0.1% against (89% of the company cast a for/against vote).
The 73 asset managers below cast 100% of the shares they voted on this item FOR (27,093,221 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,872,941 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 3,563,534 | 0 | 0 | 0 | For |
| BlackRock | 3,221,313 | 0 | 0 | 0 | For |
| Fidelity | 2,810,998 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,972,840 | 0 | 0 | 0 | For |
| State Street | 1,757,018 | 0 | 0 | 0 | For |
| TIAA | 1,195,261 | 0 | 0 | 0 | For |
| Charles Schwab | 677,479 | 0 | 0 | 0 | For |
| Prudential/PGIM | 609,924 | 0 | 0 | 0 | For |
| Federated Hermes | 578,163 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 534,643 | 0 | 0 | 0 | For |
| FINANCIAL INVESTORS TRUST | 494,279 | 0 | 0 | 0 | For |
| Principal | 480,290 | 0 | 0 | 0 | For |
| Aberdeen | 403,891 | 0 | 0 | 0 | For |
| IMPAX FUNDS SERIES TRUST I | 300,000 | 0 | 0 | 0 | For |
| Waddell & Reed | 271,855 | 0 | 0 | 0 | For |
| Equitable | 250,620 | 0 | 0 | 0 | For |
| John Hancock | 219,954 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 209,000 | 0 | 0 | 0 | For |
| JPMorgan | 190,779 | 0 | 0 | 0 | For |
| GuideStone | 161,040 | 0 | 0 | 0 | For |
| Lincoln Financial | 124,966 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 124,943 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 121,577 | 0 | 0 | 0 | For |
| Russell Investments | 114,709 | 0 | 0 | 0 | For |
Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.
Meeting held 2025-05-15.
Combines 5 wordings of this item as funds reported it.
99.4% Majority: yes · of votes cast
TRAVERE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Eric Dube, Ph.D.”): 74,221,146 for, 433,867 withheld, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 88,787,429 outstanding shares: 84% for, 0.5% withheld (84% of the company cast a for/withheld vote).
The 70 asset managers below cast 100% of the shares they voted on this item FOR (27,091,528 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,872,941 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 3,563,534 | 0 | 0 | 0 | For |
| BlackRock | 3,221,313 | 0 | 0 | 0 | For |
| Fidelity | 2,810,998 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,972,840 | 0 | 0 | 0 | For |
| State Street | 1,757,018 | 0 | 0 | 0 | For |
| TIAA | 1,195,261 | 0 | 0 | 0 | For |
| Charles Schwab | 677,479 | 0 | 0 | 0 | For |
| Prudential/PGIM | 609,924 | 0 | 0 | 0 | For |
| Federated Hermes | 578,163 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 534,643 | 0 | 0 | 0 | For |
| FINANCIAL INVESTORS TRUST | 494,279 | 0 | 0 | 0 | For |
| Principal | 480,290 | 0 | 0 | 0 | For |
| Aberdeen | 403,891 | 0 | 0 | 0 | For |
| IMPAX FUNDS SERIES TRUST I | 300,000 | 0 | 0 | 0 | For |
| Waddell & Reed | 271,855 | 0 | 0 | 0 | For |
| Equitable | 250,620 | 0 | 0 | 0 | For |
| John Hancock | 219,954 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 209,000 | 0 | 0 | 0 | For |
| JPMorgan | 190,779 | 0 | 0 | 0 | For |
| GuideStone | 161,040 | 0 | 0 | 0 | For |
| Lincoln Financial | 124,966 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 124,943 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 121,577 | 0 | 0 | 0 | For |
| Russell Investments | 114,709 | 0 | 0 | 0 | For |
Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.
Meeting held 2025-05-15.
Combines 5 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
TRAVERE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Gary Lyons”): 73,773,536 for, 881,477 withheld, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 88,787,429 outstanding shares: 83% for, 1.0% withheld (84% of the company cast a for/withheld vote).
The 70 asset managers below cast 100% of the shares they voted on this item FOR (27,091,163 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,872,941 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 3,563,534 | 0 | 0 | 0 | For |
| BlackRock | 3,221,313 | 0 | 0 | 0 | For |
| Fidelity | 2,810,998 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,972,840 | 0 | 0 | 0 | For |
| State Street | 1,757,018 | 0 | 0 | 0 | For |
| TIAA | 1,195,261 | 0 | 0 | 0 | For |
| Charles Schwab | 677,479 | 0 | 0 | 0 | For |
| Prudential/PGIM | 609,924 | 0 | 0 | 0 | For |
| Federated Hermes | 578,163 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 534,643 | 0 | 0 | 0 | For |
| FINANCIAL INVESTORS TRUST | 494,279 | 0 | 0 | 0 | For |
| Principal | 480,290 | 0 | 0 | 0 | For |
| Aberdeen | 403,891 | 0 | 0 | 0 | For |
| IMPAX FUNDS SERIES TRUST I | 300,000 | 0 | 0 | 0 | For |
| Waddell & Reed | 271,855 | 0 | 0 | 0 | For |
| Equitable | 250,620 | 0 | 0 | 0 | For |
| John Hancock | 219,954 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 209,000 | 0 | 0 | 0 | For |
| JPMorgan | 190,779 | 0 | 0 | 0 | For |
| GuideStone | 161,040 | 0 | 0 | 0 | For |
| Lincoln Financial | 124,966 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 124,943 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 121,577 | 0 | 0 | 0 | For |
| Russell Investments | 114,709 | 0 | 0 | 0 | For |
Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.
Meeting held 2025-05-15.
Combines 5 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
TRAVERE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Jeffrey Meckler”): 71,792,648 for, 2,862,365 withheld, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 88,787,429 outstanding shares: 81% for, 3% withheld (84% of the company cast a for/withheld vote).
The 70 asset managers below cast 100% of the shares they voted on this item FOR (26,932,771 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,872,941 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 3,563,534 | 0 | 0 | 0 | For |
| BlackRock | 3,221,313 | 0 | 0 | 0 | For |
| Fidelity | 2,810,998 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,972,840 | 0 | 0 | 0 | For |
| State Street | 1,757,018 | 0 | 0 | 0 | For |
| TIAA | 1,195,261 | 0 | 0 | 0 | For |
| Charles Schwab | 677,479 | 0 | 0 | 0 | For |
| Prudential/PGIM | 609,924 | 0 | 0 | 0 | For |
| Federated Hermes | 578,163 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 534,643 | 0 | 0 | 0 | For |
| FINANCIAL INVESTORS TRUST | 494,279 | 0 | 0 | 0 | For |
| Principal | 480,290 | 0 | 0 | 0 | For |
| Aberdeen | 403,891 | 0 | 0 | 0 | For |
| IMPAX FUNDS SERIES TRUST I | 300,000 | 0 | 0 | 0 | For |
| Waddell & Reed | 271,855 | 0 | 0 | 0 | For |
| Equitable | 250,620 | 0 | 0 | 0 | For |
| John Hancock | 219,954 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 209,000 | 0 | 0 | 0 | For |
| JPMorgan | 190,779 | 0 | 0 | 0 | For |
| GuideStone | 161,040 | 0 | 0 | 0 | For |
| Lincoln Financial | 124,966 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 124,943 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 121,577 | 0 | 0 | 0 | For |
| Russell Investments | 114,709 | 0 | 0 | 0 | For |
Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.
Meeting held 2025-05-15.
Combines 5 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
TRAVERE THERAPEUTICS INC.’s own tally for this item (“Elect Director: John A. Orwin”): 73,064,344 for, 1,590,669 withheld, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 88,787,429 outstanding shares: 82% for, 2% withheld (84% of the company cast a for/withheld vote).
The 70 asset managers below cast 100% of the shares they voted on this item FOR (27,037,395 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,872,941 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 3,563,534 | 0 | 0 | 0 | For |
| BlackRock | 3,221,313 | 0 | 0 | 0 | For |
| Fidelity | 2,810,998 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,972,840 | 0 | 0 | 0 | For |
| State Street | 1,757,018 | 0 | 0 | 0 | For |
| TIAA | 1,195,261 | 0 | 0 | 0 | For |
| Charles Schwab | 677,479 | 0 | 0 | 0 | For |
| Prudential/PGIM | 609,924 | 0 | 0 | 0 | For |
| Federated Hermes | 578,163 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 534,643 | 0 | 0 | 0 | For |
| FINANCIAL INVESTORS TRUST | 494,279 | 0 | 0 | 0 | For |
| Principal | 480,142 | 0 | 148 | 0 | For |
| Aberdeen | 403,891 | 0 | 0 | 0 | For |
| IMPAX FUNDS SERIES TRUST I | 300,000 | 0 | 0 | 0 | For |
| Waddell & Reed | 271,855 | 0 | 0 | 0 | For |
| Equitable | 250,620 | 0 | 0 | 0 | For |
| John Hancock | 219,954 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 209,000 | 0 | 0 | 0 | For |
| JPMorgan | 190,779 | 0 | 0 | 0 | For |
| GuideStone | 161,040 | 0 | 0 | 0 | For |
| Lincoln Financial | 124,966 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 124,943 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 121,577 | 0 | 0 | 0 | For |
| Russell Investments | 114,709 | 0 | 0 | 0 | For |
Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.
Meeting held 2025-05-15.
Combines 5 wordings of this item as funds reported it.
99.1% Majority: yes · of votes cast
TRAVERE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Ron Squarer”): 74,003,330 for, 651,683 withheld, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 88,787,429 outstanding shares: 83% for, 0.8% withheld (84% of the company cast a for/withheld vote).
The 70 asset managers below cast 100% of the shares they voted on this item FOR (27,091,528 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,872,941 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 3,563,534 | 0 | 0 | 0 | For |
| BlackRock | 3,221,313 | 0 | 0 | 0 | For |
| Fidelity | 2,810,998 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,972,840 | 0 | 0 | 0 | For |
| State Street | 1,757,018 | 0 | 0 | 0 | For |
| TIAA | 1,195,261 | 0 | 0 | 0 | For |
| Charles Schwab | 677,479 | 0 | 0 | 0 | For |
| Prudential/PGIM | 609,924 | 0 | 0 | 0 | For |
| Federated Hermes | 578,163 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 534,643 | 0 | 0 | 0 | For |
| FINANCIAL INVESTORS TRUST | 494,279 | 0 | 0 | 0 | For |
| Principal | 480,290 | 0 | 0 | 0 | For |
| Aberdeen | 403,891 | 0 | 0 | 0 | For |
| IMPAX FUNDS SERIES TRUST I | 300,000 | 0 | 0 | 0 | For |
| Waddell & Reed | 271,855 | 0 | 0 | 0 | For |
| Equitable | 250,620 | 0 | 0 | 0 | For |
| John Hancock | 219,954 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 209,000 | 0 | 0 | 0 | For |
| JPMorgan | 190,779 | 0 | 0 | 0 | For |
| GuideStone | 161,040 | 0 | 0 | 0 | For |
| Lincoln Financial | 124,966 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 124,943 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 121,577 | 0 | 0 | 0 | For |
| Russell Investments | 114,709 | 0 | 0 | 0 | For |
Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.
Meeting held 2025-05-15.
Combines 5 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
TRAVERE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Roy D. Baynes, M.D., Ph.D.”): 73,899,556 for, 755,457 withheld, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 88,787,429 outstanding shares: 83% for, 0.9% withheld (84% of the company cast a for/withheld vote).
The 70 asset managers below cast 100% of the shares they voted on this item FOR (27,083,017 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,872,941 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 3,563,534 | 0 | 0 | 0 | For |
| BlackRock | 3,221,313 | 0 | 0 | 0 | For |
| Fidelity | 2,810,998 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,972,840 | 0 | 0 | 0 | For |
| State Street | 1,757,018 | 0 | 0 | 0 | For |
| TIAA | 1,195,261 | 0 | 0 | 0 | For |
| Charles Schwab | 677,479 | 0 | 0 | 0 | For |
| Prudential/PGIM | 609,924 | 0 | 0 | 0 | For |
| Federated Hermes | 578,163 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 534,643 | 0 | 0 | 0 | For |
| FINANCIAL INVESTORS TRUST | 494,279 | 0 | 0 | 0 | For |
| Principal | 480,290 | 0 | 0 | 0 | For |
| Aberdeen | 403,891 | 0 | 0 | 0 | For |
| IMPAX FUNDS SERIES TRUST I | 300,000 | 0 | 0 | 0 | For |
| Waddell & Reed | 271,855 | 0 | 0 | 0 | For |
| Equitable | 250,620 | 0 | 0 | 0 | For |
| John Hancock | 219,954 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 209,000 | 0 | 0 | 0 | For |
| JPMorgan | 190,779 | 0 | 0 | 0 | For |
| GuideStone | 161,040 | 0 | 0 | 0 | For |
| Lincoln Financial | 124,966 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 124,943 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 121,577 | 0 | 0 | 0 | For |
| Russell Investments | 114,709 | 0 | 0 | 0 | For |
Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.
Meeting held 2025-05-15.
Combines 5 wordings of this item as funds reported it.
99.1% Majority: yes · of votes cast
TRAVERE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Ruth Williams-Brinkley”): 74,000,702 for, 654,311 withheld, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 88,787,429 outstanding shares: 83% for, 0.8% withheld (84% of the company cast a for/withheld vote).
The 70 asset managers below cast 100% of the shares they voted on this item FOR (27,091,528 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,872,941 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 3,563,534 | 0 | 0 | 0 | For |
| BlackRock | 3,221,313 | 0 | 0 | 0 | For |
| Fidelity | 2,810,998 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,972,840 | 0 | 0 | 0 | For |
| State Street | 1,757,018 | 0 | 0 | 0 | For |
| TIAA | 1,195,261 | 0 | 0 | 0 | For |
| Charles Schwab | 677,479 | 0 | 0 | 0 | For |
| Prudential/PGIM | 609,924 | 0 | 0 | 0 | For |
| Federated Hermes | 578,163 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 534,643 | 0 | 0 | 0 | For |
| FINANCIAL INVESTORS TRUST | 494,279 | 0 | 0 | 0 | For |
| Principal | 480,290 | 0 | 0 | 0 | For |
| Aberdeen | 403,891 | 0 | 0 | 0 | For |
| IMPAX FUNDS SERIES TRUST I | 300,000 | 0 | 0 | 0 | For |
| Waddell & Reed | 271,855 | 0 | 0 | 0 | For |
| Equitable | 250,620 | 0 | 0 | 0 | For |
| John Hancock | 219,954 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 209,000 | 0 | 0 | 0 | For |
| JPMorgan | 190,779 | 0 | 0 | 0 | For |
| GuideStone | 161,040 | 0 | 0 | 0 | For |
| Lincoln Financial | 124,966 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 124,943 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 121,577 | 0 | 0 | 0 | For |
| Russell Investments | 114,709 | 0 | 0 | 0 | For |
Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.
Meeting held 2025-05-15.
Combines 5 wordings of this item as funds reported it.
99.0% Majority: yes · of votes cast
TRAVERE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Sandra Poole”): 73,951,215 for, 703,798 withheld, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 88,787,429 outstanding shares: 83% for, 0.8% withheld (84% of the company cast a for/withheld vote).
The 70 asset managers below cast 100% of the shares they voted on this item FOR (27,083,018 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,872,941 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 3,563,534 | 0 | 0 | 0 | For |
| BlackRock | 3,221,313 | 0 | 0 | 0 | For |
| Fidelity | 2,810,998 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,972,840 | 0 | 0 | 0 | For |
| State Street | 1,757,018 | 0 | 0 | 0 | For |
| TIAA | 1,195,261 | 0 | 0 | 0 | For |
| Charles Schwab | 677,479 | 0 | 0 | 0 | For |
| Prudential/PGIM | 609,924 | 0 | 0 | 0 | For |
| Federated Hermes | 578,163 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 534,643 | 0 | 0 | 0 | For |
| FINANCIAL INVESTORS TRUST | 494,279 | 0 | 0 | 0 | For |
| Principal | 480,290 | 0 | 0 | 0 | For |
| Aberdeen | 403,891 | 0 | 0 | 0 | For |
| IMPAX FUNDS SERIES TRUST I | 300,000 | 0 | 0 | 0 | For |
| Waddell & Reed | 271,855 | 0 | 0 | 0 | For |
| Equitable | 250,620 | 0 | 0 | 0 | For |
| John Hancock | 219,954 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 209,000 | 0 | 0 | 0 | For |
| JPMorgan | 190,779 | 0 | 0 | 0 | For |
| GuideStone | 161,040 | 0 | 0 | 0 | For |
| Lincoln Financial | 124,966 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 124,943 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 121,577 | 0 | 0 | 0 | For |
| Russell Investments | 114,709 | 0 | 0 | 0 | For |
Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.
Meeting held 2025-05-15.
Combines 5 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
TRAVERE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Suzanne Bruhn, Ph.D.”): 73,883,211 for, 771,802 withheld, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 88,787,429 outstanding shares: 83% for, 0.9% withheld (84% of the company cast a for/withheld vote).
The 70 asset managers below cast 100% of the shares they voted on this item FOR (27,091,528 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,872,941 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 3,563,534 | 0 | 0 | 0 | For |
| BlackRock | 3,221,313 | 0 | 0 | 0 | For |
| Fidelity | 2,810,998 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,972,840 | 0 | 0 | 0 | For |
| State Street | 1,757,018 | 0 | 0 | 0 | For |
| TIAA | 1,195,261 | 0 | 0 | 0 | For |
| Charles Schwab | 677,479 | 0 | 0 | 0 | For |
| Prudential/PGIM | 609,924 | 0 | 0 | 0 | For |
| Federated Hermes | 578,163 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 534,643 | 0 | 0 | 0 | For |
| FINANCIAL INVESTORS TRUST | 494,279 | 0 | 0 | 0 | For |
| Principal | 480,290 | 0 | 0 | 0 | For |
| Aberdeen | 403,891 | 0 | 0 | 0 | For |
| IMPAX FUNDS SERIES TRUST I | 300,000 | 0 | 0 | 0 | For |
| Waddell & Reed | 271,855 | 0 | 0 | 0 | For |
| Equitable | 250,620 | 0 | 0 | 0 | For |
| John Hancock | 219,954 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 209,000 | 0 | 0 | 0 | For |
| JPMorgan | 190,779 | 0 | 0 | 0 | For |
| GuideStone | 161,040 | 0 | 0 | 0 | For |
| Lincoln Financial | 124,966 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 124,943 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 121,577 | 0 | 0 | 0 | For |
| Russell Investments | 114,709 | 0 | 0 | 0 | For |
Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.
Meeting held 2025-05-15.
Combines 5 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
TRAVERE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Timothy Coughlin”): 73,659,261 for, 995,752 withheld, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 88,787,429 outstanding shares: 83% for, 1% withheld (84% of the company cast a for/withheld vote).
The 70 asset managers below cast 100% of the shares they voted on this item FOR (26,979,538 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,872,941 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 3,563,534 | 0 | 0 | 0 | For |
| BlackRock | 3,221,313 | 0 | 0 | 0 | For |
| Fidelity | 2,810,998 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,972,840 | 0 | 0 | 0 | For |
| State Street | 1,757,018 | 0 | 0 | 0 | For |
| TIAA | 1,195,261 | 0 | 0 | 0 | For |
| Charles Schwab | 677,479 | 0 | 0 | 0 | For |
| Prudential/PGIM | 609,924 | 0 | 0 | 0 | For |
| Federated Hermes | 578,163 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 534,643 | 0 | 0 | 0 | For |
| FINANCIAL INVESTORS TRUST | 494,279 | 0 | 0 | 0 | For |
| Principal | 480,290 | 0 | 0 | 0 | For |
| Aberdeen | 403,891 | 0 | 0 | 0 | For |
| IMPAX FUNDS SERIES TRUST I | 300,000 | 0 | 0 | 0 | For |
| Waddell & Reed | 271,855 | 0 | 0 | 0 | For |
| Equitable | 250,620 | 0 | 0 | 0 | For |
| John Hancock | 219,954 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 209,000 | 0 | 0 | 0 | For |
| JPMorgan | 190,779 | 0 | 0 | 0 | For |
| GuideStone | 161,040 | 0 | 0 | 0 | For |
| Lincoln Financial | 124,966 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 124,943 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 121,577 | 0 | 0 | 0 | For |
| Russell Investments | 114,709 | 0 | 0 | 0 | For |
Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.
Meeting held 2024-05-08 (outside the 2024-2025 season's 1 July to 30 June window; reported in this season's filings).
Combines 2 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
TRAVERE THERAPEUTICS INC.’s own tally for this item (“Proposal 3: Approval, on an advisory basis, of the compensation of the Company's named executive officers The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive offic”): 55,789,526 for, 2,854,506 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 88,787,429 outstanding shares: 63% for, 3% against (66% of the company cast a for/against vote).
The 2 asset managers below cast 100% of the shares they voted on this item FOR (300 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| COLDSTREAM CAPITAL MANAGEMENT INC | 300 | 0 | 0 | 0 | For |
| Echo45 Advisors LLC | 0 | 0 | 0 | 0 | -- |
Showing the 14 reported items with the widest manager coverage, of 15 in total. View every item.
Ranked by the number of TRAVERE THERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 88,787,429 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Janus Henderson | 8.10% |
| 2 | ARMISTICE CAPITAL, LLC | 8.02% |
| 3 | BlackRock | 7.11% |
| 4 | Vanguard | 5.71% |
| 5 | State Street | 5.71% |
| 6 | MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST | 4.89% |
| 7 | Fidelity | 4.34% |
| 8 | Delaware/Macquarie | 4.01% |
| 9 | Rock Springs Capital Management LP | 3.43% |
| 10 | VIKING GLOBAL INVESTORS LP | 3.06% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| JANUS HENDERSON GROUP PLC | 11.94% | 13G |
| BlackRock | 9.22% | 13F |
| Vanguard Group | 5.65% | 13F |
| Rock Springs Capital Management LP | 5.60% | DEF14A |
| Armistice Capital, LLC | 5.52% | 13G |
| Perceptive Advisors LLC | 4.82% | 13G |
| State Street | 4.11% | 13F |
| Renaissance Technologies | 3.04% | 13F |
| Woodline Partners LP | 2.38% | 13G |
| Geode Capital | 2.23% | 13F |
Percentages above are of 88,787,429 shares outstanding, as reported by TRAVERE THERAPEUTICS INC. on its Form 10-Q dated 2025-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from TRAVERE THERAPEUTICS INC.’s 10-Q dated 2025-03-31. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.
At TRAVERE THERAPEUTICS INC.'s shareholder meeting held 2025-05-15, in the 2024-2025 proxy season, 233 asset managers reported how they voted in their SEC Form N-PX filings, covering 2,911 separate fund positions. Their filings are grouped here into 15 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers. — FOR was 96% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: TRAVERE THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission (filing date not recorded for this item).
TRAVERE THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.